- JP-listed companies
- ADR120S, Inc.
- Income statement
ADR120S, Inc. (3750) Income statement
Market cap
¥7.1B
P/E ratio
357.9x
Saitori Cell Research Institute develops regenerative cell therapies and medical devices while also investing in real estate projects through seven subsidiaries.
| 2012/03 | 2013/03 | 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Revenue | 2,908 | 2,316 | 3,531 | 4,076 | 2,684 | 2,693 | 522 | 1,925 | 1,180 | 1,388 | 1,336 | 2,145 | 1,560 | 122 | 50 |
| Revenue growth (%) | - | ||||||||||||||
| Cost of revenue | - | - | - | 2,837 | 2,124 | 2,646 | 221 | 1,436 | 424 | 628 | 476 | 876 | 268 | 128 | 40 |
| Gross profit | - | - | - | 1,239 | 561 | 47 | 301 | 489 | 756 | 760 | 859 | 1,269 | 1,293 | -6 | 11 |
| Gross margin (%) | - | - | - | ||||||||||||
| Operating margin (%) | - | - | - | ||||||||||||
| Operating expenses | - | - | - | 819 | 804 | 445 | 171 | 195 | 885 | 1,492 | 1,322 | 2,063 | 2,065 | 801 | 917 |
| Operating income | - | - | - | 420 | -243 | -398 | 130 | 293 | -129 | -732 | -462 | -794 | -773 | -807 | -906 |
| Income before tax | -78 | -62 | 300 | 401 | -247 | -398 | 128 | 204 | -185 | -746 | -418 | -862 | -907 | -865 | -922 |
| Pretax margin (%) | -2.7 | -2.7 | 8.5 | 9.8 | -9.2 | -14.8 | 24.4 | 10.6 | -15.7 | -53.7 | -31.3 | -40.2 | -58.1 | -707.8 | -1,844 |
| Provision for income taxes | - | - | - | 88 | 42 | 2 | 2 | 2 | 2 | 121 | 12 | -106 | -1,150 | -13 | -1 |
| Effective tax rate (%) | - | - | - | ||||||||||||
| Net income | -350 | -74 | -56 | 121 | 34 | -464 | 450 | 593 | 319 | -775 | -77 | -1,060 | 139 | -2,140 | -397 |
| Earnings per share | -248.75 | 201.5 | 296.81 | 84.04 | 23.75 | -329.05 | 66.25 | 88.3 | 47.58 | -101.64 | -8.79 | -118.71 | 15.47 | -239.7 | -44.46 |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | 15.42 | - | - |
| Dividend payout ratio (%) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per share | - | - | - | - | - | - | - | - | 10 | - | - | - | - | - | - |